|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Antiviral Agents
|
Sofosbuvir(PSI-7977)
| Catalogue No. : |
C14739 |
| Product Name: |
Sofosbuvir(PSI-7977) |
| Synonym: |
PSI 7977;Sofosbuvir;GS-7977;PSI7977 |
| Chemical Name: |
N-[[P(S),2'R]-2'-Deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-L-alanine 1-methylethyl ester;Isopropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate |
| CAS No. : |
1190307-88-0 |
| Structure : |
|
| Molecular Formula: |
C22H29FN3O9P |
| Molecular Weight: |
529.45 |
| Solubility: |
DMSO |
| Purity: |
>98% |
| Usage: |
PSI-7977 is an investigational nucleotide analog currently in Phase 2 for treatment of chronic HCV infection. PSI-7851 is a mixture of two similar molecules, PSI-7976 and PSI-7977, which exist in PSI-7851 as isomers of each other. Once inside a liver cell, both molecules are rapidly converted to the same active triphosphate. Given the ability to more easily manufacture PSI-7977, and potentially advantageous in vitro characteristics, PSI-7977 was selected for further clinical development. Antiviral agents. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
